147 related articles for article (PubMed ID: 1372969)
1. [Treatment of carcinoid syndrome with a somatostatin analogue].
Döbrönte Z; Stöckert A; Végh G; Varga L
Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
[TBL] [Abstract][Full Text] [Related]
2. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
3. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
Altman AR; Tschen JA; Rice L
Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
[TBL] [Abstract][Full Text] [Related]
5. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
[TBL] [Abstract][Full Text] [Related]
6. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
7. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
[TBL] [Abstract][Full Text] [Related]
8. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
Alberts AS; Falkson G
S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
[TBL] [Abstract][Full Text] [Related]
9. Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide.
Orbach-Zinger S; Lombroso R; Eidelman LA
Can J Anaesth; 2002; 49(7):678-81. PubMed ID: 12193484
[TBL] [Abstract][Full Text] [Related]
10. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
[TBL] [Abstract][Full Text] [Related]
11. [Enteral hyperoxalosis due to therapy with a somatostatin analog].
Ranft K; Eibl-Eibesfeldt B
Dtsch Med Wochenschr; 1990 Feb; 115(5):179-81. PubMed ID: 2298134
[TBL] [Abstract][Full Text] [Related]
12. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide.
Antonelli A; Gambuzza C; Bertoni F; Baschieri L
Clin Ther; 1992; 14(2):178-84. PubMed ID: 1377097
[TBL] [Abstract][Full Text] [Related]
13. Octreotide treatment of carcinoid hypertensive crisis.
Warner RR; Mani S; Profeta J; Grunstein E
Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
[TBL] [Abstract][Full Text] [Related]
14. [Successful treatment of carcinoid syndrome in two cases of bronchial carcinoid].
Katakami N; Matsumoto H; Ishihara K; Umeda B
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Nov; 33(11):1313-8. PubMed ID: 8583728
[TBL] [Abstract][Full Text] [Related]
15. SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization.
Ahlman H; Ahlund L; Dahlström A; Martner J; Stenqvist O; Tylén U
Anesth Analg; 1988 Dec; 67(12):1142-8. PubMed ID: 2461665
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
17. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
[TBL] [Abstract][Full Text] [Related]
19. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
